Comparisons of effectiveness and safety between on-label dosing, off-label underdosing, and off-label overdosing in Asian and non-Asian atrial fibrillation patients …
YH Chan, CY Chan, SW Chen, TF Chao, GYH Lip - Europace, 2023 - academic.oup.com
Aims Limited real-world data show that rivaroxaban following dosage criteria from either
ROCKET AF [20 mg/day or 15 mg/day if creatinine clearance (CrCl)< 50 mL/min] or J …
ROCKET AF [20 mg/day or 15 mg/day if creatinine clearance (CrCl)< 50 mL/min] or J …
Clinical consequences of off-label reduced dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a systematic review and meta …
LPT Joosten, R van Maanen, CJ van den Dries… - Open …, 2023 - openheart.bmj.com
Objective Postmarketing observational studies report that a substantial percentage of
patients with atrial fibrillation (AF) receive a reduced non-vitamin K antagonist oral …
patients with atrial fibrillation (AF) receive a reduced non-vitamin K antagonist oral …
Off-Label Reduced Dose Apixaban in Older Adults With Atrial Fibrillation and Associated Outcomes
AM Campbell, E Pae, E Lee, T Jacisin… - Annals of …, 2024 - journals.sagepub.com
Background: Apixaban is commonly used to prevent stroke in older adults with nonvalvular
atrial fibrillation (AF). Although its package insert has specific dose reduction criteria …
atrial fibrillation (AF). Although its package insert has specific dose reduction criteria …
[HTML][HTML] Systematic review: Clinical consequences of off-label reduced dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a …
LPT Joosten, R van Maanen, CJ van den Dries… - Open Heart, 2023 - ncbi.nlm.nih.gov
Objective Postmarketing observational studies report that a substantial percentage of
patients with atrial fibrillation (AF) receive a reduced non-vitamin K antagonist oral …
patients with atrial fibrillation (AF) receive a reduced non-vitamin K antagonist oral …
Prevalence, contemporary trends and associated factors of potentially inappropriate prescription of edoxaban in real‐world clinical practice: A subanalysis of the …
S Zhao, H Dai, J Chen, M Ni, W Peng… - British Journal of …, 2024 - Wiley Online Library
Aim As the direct oral anticoagulant most recently approved in China, data pertaining to
clinical edoxaban use are still scarce. This study investigated the prevalence of and …
clinical edoxaban use are still scarce. This study investigated the prevalence of and …
[HTML][HTML] A real-world study of different doses of rivaroxaban in patients with nonvalvular atrial fibrillation
X Yan, L Zhang, D Zhang, X Wang - Medicine, 2024 - journals.lww.com
To explore the anticoagulant effect and safety of utilizing different doses of rivaroxaban for
the treatment of patients with atrial fibrillation (AF) in the real world. A retrospective case …
the treatment of patients with atrial fibrillation (AF) in the real world. A retrospective case …